Paradigm’s strategic management is driven by a team with significant experience in drug development and the execution of clinical studies.
Executive Leadership Team
Our Chief Executive Officer, Mr Paul Rennie, has been involved in drug development and a number of pre-clinical and clinical trial programs (was the inaugural COO of Mesoblast and most recently as Executive VP, New Product Development at Mesoblast Ltd). Mr. Rennie has extensive experience in commercialising Intellectual Property.
Our Chief Scientific Officer, Dr Ravi Krishnan, is a basic scientist with a long-standing interest and experience in experimental pathology, transplantation immunology, gene and stem cell therapy. He has also had significant experience in investigating novel compounds with immune modulatory effects, anti-inflammatory and anti-angiogenic properties.
Director of Investor Relations, Simon White, joined the Paradigm team in January 2020. Simon has a wide range of experience in the financial services sector, with previous roles including Corporate Advisory at DELCOR, a Melbourne based Family Office, and Institutional Sales at Sequoia Wealth Management. As a former AFL footballer for Carlton, Simon brings a unique combination of skills. Having spent 8 years as a high-performing professional athlete, Simon’s team-orientated approach and networking skills make a highly valuable contribution to the team.
Our Chief Medical Officer and Executive Director, Dr. Donna Skerrett, joined the Paradigm team in September 2019. Dr. Skerrett, has more than 30 years’ experience in transfusion medicine, cellular therapy, and regenerative medicine. Dr. Skerrett was the Chief Medical Officer of Mesoblast a stem cell development company from 2011-2019. She was Director of Transfusion Medicine and Cellular Therapy at Weill Cornell Medical Center in New York from 2004 – 2011 and prior to that was Associate Director of Transfusion Medicine at Columbia University’s New York-Presbyterian Hospital. She has previously chaired the New York State Governor’s Council on Blood and Transfusion Service and served on the Board of Directors of the Fox Chase Cancer Center. She currently serves in an advisory role on the Board of Visitors for the Lewis Katz School of Medicine of Temple University.
Our Chief Financial Officer, Justin Cahill, has over 20 years’ experience in strategic finance roles across a broad spectrum of industries and global organisations. nIn one of his prominent roles, Justin spent 9 years at CSL, including 5 years as Divisional CFO of CSL Plasma. Justin is a CPA and holds a Master’s in Accounting. As Paradigm’s operations expand and become more global, Justin will oversee the financial management of, and control over, Paradigm’s increasingly complex activities.
Our Global Head of Regulatory Affairs, Michelle Coffey, has over 20 years global experience in the pharmaceutical industry (Chemical and Biological), covering the life cycle of a product from early stage clinical right through to commercial launch and maintenance. She has extensive knowledge in global regulatory requirements, working on areas including emerging treatments and clinical protocols for cell therapy products and technologies. She has worked on cross-functional teams in order to develop effective product strategy, and ensure submission timelines and global regulatory requirements are met.
Executive Chairman and CEO
Paul Rennie BSc, MBM, Grad Dip Commercial Law, MSTC, has sales, marketing, business development, operational and IP commercialisation experience in the biopharmaceutical sector. Paul’s experience includes working for Boehringer Mannheim (now Roche Diagnostics), Merck KGGA as national sales and marketing manager and Soltec (FH Faulding Ltd) as their director of business development. Paul also led the commercialisation of Recaldent® a novel biopharmaceutical arising from research at the dental school, University of Melbourne. Paul took an R&D project from the laboratory bench to a commercial product now marketed globally as an additive to oral care products. More recently Paul worked in a number of positions with Mesoblast Ltd. Paul was the inaugural COO and moved into Executive Vice President New Product Development for the adult stem cell company.
With over 30 years of experience in transfusion medicine, cellular therapy, and transplantation, she brings a wealth of experience in medical, clinical, and regulatory affairs. Donna served previously as Chief Medical Officer at Mesoblast. She was Director of Transfusion Medicine and Cellular Therapy at Weill Cornell Medical Center in New York (2004 – 2011), and before that was Associate Director of Transfusion Medicine and Director of Stem Cell Facilities at Columbia University’s New York-Presbyterian Hospital. She previously chaired the New York State Council on Blood and Transfusion Services and currently serves on the Board of Directors of the Fox Chase Cancer Center in Philadelphia, Pa.
Helen is CEO and managing director of Cio Capital Impact Fund (BCIF) and Non – Executive Director (NED) and Chair of the Audit and Risk Committee of Calic Limited (ASX: CXL), a company with a platform technology with applications in climate change, water management, biotech, and pharmaceutical areas. Prior to establishing BCIF, Helen was a partner of Deloitte and led Deloitte’s life science practice in Australia for 5 years, having had many years’ experience in the life sciences and health care sector.
John Gaffney LL.M is a lawyer with over 30 years of experience and has undertaken the AICD Company Directors qualification. He brings to the board compliance and corporate governance background and is experienced in financial services compliance. John also has corporate and commercial experience having worked with a major national law firm as a senior lawyer and also practised as a Barrister at the Victorian Bar. Previously John has previously been a non executive director of a US based biotechnology company and a non – executive director of SelfWealth Ltd (ASX: SWF).
Kevin Hollingsworth, FCPA, FCMA, CGMA, in addition to his duties at Paradigm, serves as Principal of Hollingsworth Financial Services. Prior to that, he served as Chief Financial Officer and Company Secretary of Mesoblast Limited (ASX: MSB). At Alpha Technologies Corporation Limited (ASX: ASU), Kevin Hollingsworth served as a Non-Executive Director. He is a Chartered Global Management Accountant and Fellow of CPA Australia and Chartered Management Accountants.
Amos Meltzer is a scientist and an intellectual property lawyer with over 25 years of experience in international trade and in commercialising technologies principally in the life sciences sector. He has presided over life science research and product development projects clinical trials as well as the commercialisation of life sciences assets through both licensing and the sale and marketing of a pharmaceutical product. Previously Amos has served as in house counsel and IP director at two Nasdaq-listed companies Cgen and Gilat, as a non-executive director of a biotechnology company Evogene and as VP of Business Development and then CEO of an ASX-listed biopharmaceutical company Immuron. Amos currently serves as Chief Operating Officer of neuro-medical device company Synchron, chairman of the board of surgeons’ education services company Vasculab and as a legal advisor to a number of ASX listed and private life science companies.